Hepatitis D Epidemiology Forecast 2026-2035

Hepatitis D is estimated to affect approximately 5% of individuals with chronic hepatitis B virus infection globally, reflecting a significant hepatitis D prevalence burden. According to the World Health Organization, co-infection with hepatitis D and hepatitis B can accelerate progression toward hepatocellular carcinoma and liver-related mortality, highlighting the severe clinical implications associated with this viral condition. As per the Hepatitis D epidemiology forecast, the global burden of hepatitis D is expected to remain substantial, driven by persistent hepatitis B prevalence and regional disparities in screening, diagnosis, and access to treatment.

Hepatitis D Epidemiology Forecast Report Coverage

The analyst's “Hepatitis D Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hepatitis D. It projects the future incidence and prevalence rates of hepatitis D cases across various populations. The study covers age, gender, and type as major determinants of the hepatitis D population. The report highlights patterns in the prevalence of hepatitis D over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of amblyopia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hepatitis D Understanding: Disease Overview

Hepatitis D (HDV) is a viral infection that occurs only in individuals already infected with hepatitis B, aligning with hepatitis delta virus co-infection epidemiology patterns. The infection accelerates liver disease progression, leading to cirrhosis and liver cancer. Transmission occurs through contact with infected blood, including needle sharing and unsafe medical practices. Common symptoms include jaundice, fatigue, abdominal pain, and dark urine, reflecting systemic liver dysfunction.

Hepatitis D Epidemiology Perspective

The hepatitis D epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the hepatitis D epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hepatitis D and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The World Health Organization states that approximately 5% of individuals with chronic hepatitis B infection are affected by hepatitis D, indicating a notable HBV-HDV co-infection burden globally.
• More than 90% of patients with active hepatitis B who acquire hepatitis D develop chronic infection lasting over six months, reflecting persistent chronic hepatitis D progression trends.
• In the United States, around 100,000 individuals are estimated to have combined HBV and HDV infection, highlighting viral hepatitis co-infection prevalence patterns.
• A 2020 study in the Journal of Hepatology reported that HDV co-infection accounts for approximately one in five liver disease and cancer cases in HBV patients, indicating a substantial liver disease risk associated with HDV.

Country-wise Hepatitis D Epidemiology

The hepatitis D epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hepatitis D varies significantly between countries due to differences in hepatitis B prevalence, healthcare access, and risk behaviors, reflecting a distinct geographic hepatitis D distribution pattern. Public health interventions such as hepatitis B vaccination have contributed to reduced transmission in several regions. In the United States, Wong et al. (2024) estimated that approximately 1.97 million individuals were living with chronic hepatitis B (CHB), including around 75,005 individuals with hepatitis D virus (HDV) infection in 2022, highlighting a notable burden of HDV among HBV-infected populations. In Europe, prevalence among hepatitis B surface antigen (HBsAg)-positive populations generally ranges between 5% and 10% in countries such as Germany, Italy, Spain, and France, influenced by migration patterns from high-endemic regions.

Hepatitis D: Treatment Overview

Pegylated interferon-alpha remains the primary treatment for chronic hepatitis D, working to reduce viral replication and improve liver function, reflecting established hepatitis D treatment response patterns. In advanced cases with cirrhosis or liver failure, liver transplantation may be required. Since HDV depends on HBV infection, vaccination against hepatitis B is the most effective preventive strategy. Ongoing research into novel antiviral therapies continues to expand future treatment possibilities.

Key Questions Answered

• What are the key findings of hepatitis D epidemiology in the 8 major markets?
• What will be the total number of patients with hepatitis D across the 8 major markets during the forecast period?
• What was the country-wise hepatitis D epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hepatitis D patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hepatitis D during the forecast period of 2026-2035?
• What are the currently available treatments for hepatitis D?
• What are the disease risks, signs, symptoms, and unmet needs of hepatitis D?

Scope of the Hepatitis D Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hepatitis D based on several factors.
• Hepatitis D Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hepatitis D report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.